| 1 |
33662676 | Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy. | 2021 Apr 15 |
1 |
| 2 |
34673425 | JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. | 2021 Dec |
1 |
| 3 |
31371410 | Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells. | 2020 Apr |
2 |
| 4 |
31952546 | De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. | 2020 Jan 17 |
1 |
| 5 |
32272420 | Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells. | 2020 Jun 1 |
1 |
| 6 |
32999163 | Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells. | 2020 |
1 |
| 7 |
33149116 | Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. | 2020 Nov 4 |
1 |
| 8 |
30516071 | MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. | 2019 Jul |
4 |
| 9 |
29115375 | Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib. | 2018 Jan |
5 |
| 10 |
29777794 | Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. | 2018 Jul 10 |
1 |
| 11 |
30687103 | A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells. | 2018 |
2 |
| 12 |
28387753 | Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. | 2017 Apr 7 |
1 |
| 13 |
28403213 | M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. | 2017 |
2 |
| 14 |
27027438 | BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin. | 2016 Apr 26 |
2 |
| 15 |
27272942 | High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia. | 2016 Sep |
1 |
| 16 |
25953263 | Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. | 2015 Sep |
2 |
| 17 |
24487968 | Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. | 2014 Mar |
1 |
| 18 |
24675360 | BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. | 2014 May 15 |
2 |
| 19 |
25098340 | Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations. | 2014 Aug |
2 |
| 20 |
23370613 | The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells. | 2013 Apr |
1 |
| 21 |
23400594 | Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. | 2013 Apr 1 |
1 |
| 22 |
22895079 | Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. | 2012 Nov |
1 |
| 23 |
25436685 | Progress towards direct inhibitors of Stat5 protein. | 2012 Jun |
1 |
| 24 |
21091189 | Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth. | 2011 Feb |
2 |
| 25 |
21220747 | High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. | 2011 Mar 24 |
4 |
| 26 |
21224473 | Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. | 2011 Mar 10 |
1 |
| 27 |
21233313 | The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. | 2011 Mar 24 |
2 |
| 28 |
21299849 | BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. | 2011 Feb 7 |
2 |
| 29 |
21356308 | Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. | 2011 Jul |
2 |
| 30 |
20201032 | Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. | 2010 Mar |
2 |
| 31 |
20849385 | Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. | 2010 Oct |
3 |
| 32 |
17900686 | Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. | 2008 Apr |
1 |
| 33 |
18181176 | Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. | 2008 Apr |
1 |
| 34 |
18281522 | Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells. | 2008 Feb |
1 |
| 35 |
17259998 | Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. | 2007 Apr |
1 |
| 36 |
17533047 | Imatinib effect on growth and signal transduction in polycythemia vera. | 2007 Jun |
2 |
| 37 |
15604220 | Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. | 2005 Apr 15 |
1 |
| 38 |
14646349 | Apoptosis induced by molecular targeting therapy in hematological malignancies. | 2004 |
1 |
| 39 |
15277706 | Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells. | 2004 |
1 |
| 40 |
12764361 | In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. | 2003 Jun |
5 |
| 41 |
12804638 | Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications. | 2003 Sep |
1 |
| 42 |
14604282 | Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes. | 2003 Oct |
1 |
| 43 |
11782377 | Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. | 2002 Jan 1 |
1 |
| 44 |
12483533 | Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. | 2002 Dec 12 |
1 |
| 45 |
11313280 | Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. | 2001 May 1 |
1 |